The medical director of the Westport Headache Institute spoke to the role that devices can play in layered and variable treatment approaches, and how this better lends itself to offering personalized treatment to different individuals with migraine
“I certainly see a role for rimegepant [in the mini-prevention approach to menstrual migraine], and the e-TNS device. Especially if we come to find that not enough tablets were approved [by the patient’s insurer] of rimegepant, then we may have to supplement with neuromodulation.”
Many headache specialists have been looking into layered approaches to migraine treatment, particularly in light of the recent FDA approval of rimegepant (Nurtec ODT; Biohaven) for the prevention of migraine—making it the only gepant approved to treat the headache disorder both acutely and preventatively. Many nonpharmacologic devices can be used in both fashions or may be able to fill the treatment roles in a layered approach.
Deena Kuruvilla, MD, medical director, Westport Headache Institute, presented data at the 2021 American Headache Society (AHS) Annual Scientific Meeting, June 3-6, from the TEAM study (NCT03465904) of external trigeminal nerve stimulation (e-TNS), done with one such device, the Cefaly device. Her presentation revealed that the device displayed superiority to a sham device in providing 2-hour pain freedom and freedom from the most bothersome symptom (MBS), as well as sustained pain freedom at 24 hours, in a population of patients with migraine.
To find out more about the role that such devices can play in layered and variable treatment approaches, and how this better lends itself to offering personalized treatment to different individuals with migraine, NeurologyLive spoke down with Kuruvilla.
For more coverage of AHS 2021, click here.